Följ
Razelle Kurzrock, MD
Razelle Kurzrock, MD
Professor of Medicine, Medical College of Wisconsin
Verifierad e-postadress på mcw.edu
Titel
Citeras av
Citeras av
År
PD-L1 expression as a predictive biomarker in cancer immunotherapy
SP Patel, R Kurzrock
Molecular cancer therapeutics 14 (4), 847-856, 2015
21412015
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers
AM Goodman, S Kato, L Bazhenova, SP Patel, GM Frampton, V Miller, ...
Molecular cancer therapeutics 16 (11), 2598-2608, 2017
20422017
The biology of chronic myeloid leukemia
S Faderl, M Talpaz, Z Estrov, S O'Brien, R Kurzrock, HM Kantarjian
New England Journal of Medicine 341 (3), 164-172, 1999
18101999
Phase II trial of curcumin in patients with advanced pancreatic cancer
N Dhillon, BB Aggarwal, RA Newman, RA Wolff, AB Kunnumakkara, ...
Clinical cancer research 14 (14), 4491-4499, 2008
15492008
The molecular genetics of Philadelphia chromosome–positive leukemias
R Kurzrock, JU Gutterman, M Talpaz
New England Journal of Medicine 319 (15), 990-998, 1988
11501988
Epstein-Barr virus and cancer
MP Thompson, R Kurzrock
Clinical cancer research 10 (3), 803-821, 2004
10582004
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
GS Falchook, GV Long, R Kurzrock, KB Kim, TH Arkenau, MP Brown, ...
The Lancet 379 (9829), 1893-1901, 2012
9992012
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
N Krishnamurthy, R Kurzrock
Cancer treatment reviews 62, 50-60, 2018
9042018
Autophagy as a target for anticancer therapy
F Janku, DJ McConkey, DS Hong, R Kurzrock
Nature reviews Clinical oncology 8 (9), 528-539, 2011
8762011
Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate
S Kato, A Goodman, V Walavalkar, DA Barkauskas, A Sharabi, ...
Clinical Cancer Research 23 (15), 4242-4250, 2017
8512017
Liposome‐encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
L Li, FS Braiteh, R Kurzrock
Cancer: Interdisciplinary International Journal of the American Cancer …, 2005
7902005
Clinical toxicity of interferons in cancer patients: a review.
JR Quesada, M Talpaz, A Rios, R Kurzrock, JU Gutterman
Journal of Clinical Oncology 4 (2), 234-243, 1986
7701986
The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing
T Helsten, S Elkin, E Arthur, BN Tomson, J Carter, R Kurzrock
Clinical cancer research 22 (1), 259-267, 2016
6872016
Chronic myelogenous leukemia: a concise update
HM Kantarjian, A Deisseroth, R Kurzrock, Z Estrov, M Talpaz
6471993
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer
R Kurzrock, SI Sherman, DW Ball, AA Forastiere, RB Cohen, R Mehra, ...
Journal of Clinical Oncology 29 (19), 2660, 2011
6142011
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
GS Falchook, KD Lewis, JR Infante, MS Gordon, NJ Vogelzang, ...
The lancet oncology 13 (8), 782-789, 2012
5922012
The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato, R Kurzrock
Cancer cell 39 (2), 154-173, 2021
5772021
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative
AM Tsimberidou, NG Iskander, DS Hong, JJ Wheler, GS Falchook, S Fu, ...
Clinical cancer research 18 (22), 6373-6383, 2012
5742012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial
JR Infante, LA Fecher, GS Falchook, S Nallapareddy, MS Gordon, ...
The lancet oncology 13 (8), 773-781, 2012
5742012
Philadelphia chromosomepositive leukemias: from basic mechanisms to molecular therapeutics
R Kurzrock, HM Kantarjian, BJ Druker, M Talpaz
Annals of internal medicine 138 (10), 819-830, 2003
5582003
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20